SCHEMBL1867969

SCHEMBL1867969

N[C@@H](CSCCC(=O)O)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BHMT Q93088 6/20 0.62
ARG1 P05089 1/20 0.62
ARG2 P78540 1/20 0.62
KMT2A Q03164 2/20 0.56
LMNA P02545 1/20 0.56
HSD17B10 Q99714 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
NOS2 P35228 3/20 0.55
NOS1 P29475 2/20 0.55
NOS3 P29474 1/20 0.55
GRM8 O00222 2/20 0.54
GRM6 O15303 2/20 0.54
GRM7 Q14831 2/20 0.54
GRM4 Q14833 2/20 0.54
GRIN2D O15399 1/20 0.54
GRIN3B O60391 1/20 0.54
GSR P00390 1/20 0.54
CYP1A2 P05177 1/20 0.54
GRIK1 P39086 1/20 0.54
GRM5 P41594 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1867971 1.00 BHMT (0.62) BHMTARG1ARG2KMT2ALMNA
SCHEMBL7292563 0.90 BHMT (0.62) BHMTARG1ARG2KMT2ALMNA
SCHEMBL7292565 0.90 BHMT (0.62) BHMTARG1ARG2KMT2ALMNA
SCHEMBL15436097 0.90 BHMT (0.62) BHMTARG1ARG2KMT2ALMNA
SCHEMBL17361240 0.88 ARG1 (0.69) BHMTARG1ARG2NOS2NOS1
SCHEMBL17361239 0.88 ARG1 (0.69) BHMTARG1ARG2NOS2NOS1
SCHEMBL6230471 0.88 BHMT (0.71) BHMTARG1ARG2KMT2ALMNA
SCHEMBL6230473 0.88 BHMT (0.71) BHMTARG1ARG2KMT2ALMNA
SCHEMBL1106818 0.84 ARG1 (0.60) BHMTARG1ARG2KMT2ANOS2
SCHEMBL4242586 0.84 ARG1 (0.60) BHMTARG1ARG2KMT2ANOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119555822-A Urine metabolism marker composition for diagnosis of cancer seeds of pan-cancer, screening method and application 哈尔滨脉图精准技术有限公司 2025-03-04 CN claimed
CN-116120936-B Etching liquid medicine and preparation method and application thereof 上海天承化学有限公司 2024-06-25 CN claimed
CN-116120936-A Etching liquid medicine and preparation method and application thereof 上海天承化学有限公司 2023-05-16 CN claimed
CN-114438190-A Opening and closing nerve soothing soup-autism core effect gene target and screening method thereof 中国人民解放军空军军医大学 2022-05-06 CN claimed
US-20140112976-A1 Cyclic Peptides with an Anti-Neoplasic and Anti-Angiogenic Activity CENTRO DE INGENIERIA GENETICA BIOTECNOLOGIA (CU) 2014-04-24 US claimed
EP-2690107-A2 CYCLIC PEPTIDES WITH AN ANTI-NEOPLASIC AND ANTI-ANGIOGENIC ACTIVITY Centro De Ingenieria Genetica Y Biotecnologia (CU) 2014-01-29 EP claimed
EP-1282397-B1 USE OF COMPOUNDS CONTAINING A THIO-ETHER, SULPHOXIDE OR SULPHONE FUNCTION AS COSMETIC ANTI-POLLUTION AGENT OREAL (FR) 2005-05-04 EP claimed
US-20040037856-A1 Use of compounds containing a thio-ether, sulphoxide or sulphone function as cosmetic anti-pollution agent L'OREAL (FR) 2004-02-26 US claimed
EP-0858319-B1 USE OF CARBOXYLIC ACIDS HAVING A SULPHUR FUNCTION FOR PROMOTING SKIN EXFOLIATION OR STIMULATING EPIDERMAL REGENERATION OREAL (FR) 2003-07-23 EP claimed
EP-1282397-A1 USE OF COMPOUNDS CONTAINING A THIO-ETHER, SULPHOXIDE OR SULPHONE FUNCTION AS COSMETIC ANTI-POLLUTION AGENT L'OREAL (FR) 2003-02-12 EP claimed
WO-2001087261-A1 USE OF COMPOUNDS CONTAINING A THIO-ETHER, SULPHOXIDE OR SULPHONE FUNCTION AS COSMETIC ANTI-POLLUTION AGENT L'OREAL (FR) 2001-11-22 WO claimed
US-6153649-A Use of carboxylic acids having a sulphur function for promoting skin exfoliation or stimulating epidermal regeneration L'OREAL (FR) 2000-11-28 US claimed
EP-0858319-A1 USE OF CARBOXYLIC ACIDS HAVING A SULPHUR FUNCTION FOR PROMOTING SKIN EXFOLIATION OR STIMULATING EPIDERMAL REGENERATION L'OREAL (FR) 1998-08-19 EP claimed
WO-1997016165-A1 USE OF CARBOXYLIC ACIDS HAVING A SULPHUR FUNCTION FOR PROMOTING SKIN EXFOLIATION OR STIMULATING EPIDERMAL REGENERATION L'OREAL (FR) 1997-05-09 WO claimed
EP-0588335-B1 Separation column and method for preventing its deterioration HITACHI LTD (JP) 1997-02-05 EP claimed
US-5407568-A Separation column containing S-carboxyalkylcysteine HITACHI, LTD. (JP) 1995-04-18 US claimed
EP-0588335-A1 Separation column and method for preventing its deterioration HITACHI, LTD. (JP) 1994-03-23 EP claimed
US-20260083852-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR UNIV CALIFORNIA (US) 2026-03-26 US disclosed
US-4151301-A ANTISECRETORY L'OREAL (FR) 1979-04-24 US disclosed
US-4002671-A REDUCE SEBUM SECRETION ON SCALP OR SKIN SOCIETE ANONYME DITE: L'OREAL (FR) 1977-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040037856-A1 Use of compounds containing a thio-ether, sulphoxide or sulphone function as cosmetic anti-pollution agent TST, STS, MPST BHMT 1437/4885ARG1 3597/4885ARG2 2687/4885
US-20260083852-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR PDGFA, DCLRE1A, PDGFRA BHMT 3732/4885ARG1 557/4885ARG2 1295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.